[Summary] Overall solutions in the field of mass spectrometry detection
Beijing Haosi Biotechnology Co., Ltd. is a high-tech platform enterprise based on mass spectrometry technology, with extensive experience in research and development related to early diagnosis, treatment, and monitoring of Alzheimer's disease. By using liquid chromatography-mass spectrometry (LC-MS) technology for quantitative detection of "cognitive protein", it can screen for the risk of Alzheimer's disease at an early stage; independently developed the Haosi cocktail therapy, which can provide targeted supplementation of "cognitive" proteins, delay the onset of the disease, and improve patients' cognitive abilities.
Haosi Biotechnology is a research-oriented high-tech enterprise founded by returnees from overseas studies. The company's R&D and senior management team consists of multiple senior scholars and entrepreneurs who studied in Europe and the United States, with rich experience in medical technology R&D and management operations. Core members are all graduates of Peking University, Tsinghua University, and overseas Ph.D. holders. The company has independently developed a series of clinical mass spectrometry screening products. The above research findings have applied for 12 Chinese patents, and international patent protection is being submitted simultaneously.
Haosi Biotechnology's mission is to improve the health status and quality of life of patients with neurological diseases, especially Alzheimer's patients, by developing in vitro diagnostic reagents and third-class medical technology therapies based on mass spectrometry technology. The company uses world-leading mass spectrometry omics platforms to develop and identify specific early diagnostic biomarkers in blood related to cardiovascular, cerebrovascular, and neurological diseases.
Haosi Biotechnology is also a mass spectrometry omics experimental service provider, serving large domestic hospitals and clinical testing centers, providing comprehensive clinical metabolomics, lipidomics, and proteomics testing services. Independent clinical mass spectrometry diagnostic laboratories (Clia Lab) have established mature systems and markets in developed regions such as the United States and Europe, but in China, this is only just beginning. Haosi Biotechnology's goal is to introduce mature Western testing projects and technologies into the domestic medical system, while internationalizing innovative tests independently developed based on a large number of clinical cases in China.
What does Beijing Haosi Biotechnology Co., Ltd. require? Who is Haosi Biotechnology hiring? Haosi Biotechnology recruitment: 其他（研发和技术类）占比最多占21.1%，其次是市场/公关/媒介类占21.1%. What education can get in at Haosi Biotechnology? 大专占比最多占42.1%，其次是本科占31.6%. High education required at Haosi Biotechnology? 硕士占26.3%. Work experience required at Haosi Biotechnology? 1-3年占比最多占42.1%，其次是3-5年占42.1%. Where are the job locations at Haosi Biotechnology? 苏州占比最多占31.6%，其次是西安占26.3%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
